Lunai Bioworks Inc 's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lunai Bioworks Inc 's ROA in the fourth quarter of 2026?
Lunai Bioworks Inc recorded a cumulative net loss of $-4 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -38.83%.

However, within the Healthcare sector 493 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4721, from total ROA ranking in the third quarter of 2026 at 5337.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	-18.02 %	-91.62 %	-94.95 %	-94.28 %	-95.59 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-4	-128	-126	-131	-178
Return On Assets (TTM)	-38.83 %	-1306.99 %	-341.27 %	-173.46 %	-170.85 %
LNAI's Total Ranking	# 4721	# 5337	# 4591	# 4669	# 4137
Total Assets (TTM) in million	12	10	8	7	14
Seq. Total Assets Change	18.13 %	19.8 %	18.25 %	-51.01 %	-87.93 %
Seq. Net Income Change	-	-	-	-	-

LNAI's 5 Years Annual ROA >> Back to LNAI Management Effectiveness >> Compare LNAI ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 197
Sector	# 494
Overall	# 3779

Return On Assets Statistics
High	Average	Low
-0.19 %	-343.29 %	-9636.18 %
		(Dec 31 2013)

Financial Statements
Lunai Bioworks Inc 's Assets	$ 12 million	LNAI's Balance sheet
Lunai Bioworks Inc 's Income	$ -2 million	Quarterly LNAI's Income Statement
LNAI's Income by Division		See LNAI's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	41.52 %	-94.95 %	184.26 %	-32.19 %	-55.02 %
Total Assets in million	12	8	163	57	85
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-4	-178	-88	-40	-113
Annual Return On Assets	-30.58 %	-2162.68 %	-54.21 %	-69.15 %	-134.03 %

LNAI's 5 Years Annual ROA >> Back to LNAI Management Effectiveness >> Compare LNAI ROA to its Competitors

More Return On Assets Ratios
LNAI's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LNAI's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LNAI's Competitors
Subscribers only: Roa for Lunai Bioworks Inc 's Suppliers
Subscribers only: Return On Assets for LNAI's Customers

You may also want to know
LNAI's Roi	LNAI's Inventory Turnover Ratio	LNAI's Growth Rates	LNAI's Dividend Comparisons
	LNAI's Profitability Ratios	LNAI's Asset Turnover Ratio	LNAI's Dividend Growth
LNAI's Roe	LNAI's Valuation Ratios	LNAI's Financial Strength Ratios	LNAI's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-10-17T06:30:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.